Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01596699 · ClinicalTrials.gov registry record · Phase 2
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01596699 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 16 participants.
The verdict
NCT01596699, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects, good and/or bad, the addition of clofarabine, a new chemotherapy agent, to a standard busulfan and fludarabine conditioning treatment has. The study will also look at what causes some people to have high drug levels of these medications in their body compared to other people that may have low drug levels even if they all receive the same dose of medication.
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Alemtuzumab
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-05-24 |
| Est. Completion | 2019-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01596699
The ClinicalTrials.gov registry entry for NCT01596699 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fludarabine is the first listed.
NCT01596699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01596699 about?
NCT01596699 is a clinical study titled "Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation". The purpose of this study is to find out what effects, good and/or bad, the addition of clofarabine, a new chemotherapy agent, to a standard busulfan and fludarabine conditioning treatment has. The study will also look at what causes some people to have high drug levels of these medications in their...
What is the current status of trial NCT01596699?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2012-05-24. Estimated completion is 2019-06.
What interventions are being tested in trial NCT01596699?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Alemtuzumab (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT01596699?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.